603077:SSESichuan Hebang Biotechnology Co. Ltd. Class A Analysis

Sichuan Hebang Biotechnology is riding a strong technical rally, with the 20‑day SMA comfortably above the 50‑day and 200‑day averages and a bullish MACD crossover confirming upward momentum. RSI is perched in the mid‑70s, signaling an overbought condition, while volume is accelerating and price has touched the 52‑week high, meeting the identified resistance level. Fundamentally, the picture is less encouraging: the company posted a negative profit margin, modest revenue growth, and a high debt‑to‑equity ratio, while the DCF‑derived fair value sits well below the current market price. The dividend yield is under 1% with a low payout ratio, but negative free cash flow raises questions about sustainability. In the near term, the stock may face a pull‑back as momentum wanes, yet the forward earnings outlook offers a modest upside if the company can improve profitability and manage leverage.